<DOC>
	<DOCNO>NCT02518620</DOCNO>
	<brief_summary>The objective study evaluate long-term efficacy safety ALX-0061 administer subcutaneously ( s.c. ) subject active Rheumatoid Arthritis ( RA ) .</brief_summary>
	<brief_title>An Extension Study Assessing Long-Term Efficacy Safety Subcutaneous ALX-0061 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Must eligible one precede Phase IIb study ALX 0061 ( study ALX0061C201 ALX0061C202 ) , randomize placebo one ALX0061 arm ( subject randomize tocilizumab [ TCZ ] study ALX0061C202 eligible ) . Must reach response end treatment visit precede Phase IIb ALX0061C201 , ALX0061C202 study . Others define protocol Received tocilizumab previous Study ALX0061C202 . Others define protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>